Location
Hyatt Regency Denver at Colorado Convention Center
650 15th Street
Denver, Colorado
Hotel Phone: (303) 436-1234
Program Schedule — Mountain Time
5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 8:00 PM — Educational Meeting
Meeting Room
Capitol Ballroom (Fourth Floor)
Faculty Virginia F Borges, MD, MMSc
Professor of Medicine with Tenure
Robert F and Patricia Young-Connor Endowed Chair in Young Women’s Breast Cancer Research
Deputy Head, Division of Medical Oncology
Director, Breast Cancer Research Program and
Young Women’s Breast Cancer Translational Program
University of Colorado Cancer Center
Aurora, Colorado
Jamie Carroll, APRN, MSN, CNP
Assistant Professor, Oncology
Mayo Clinic
Rochester, Minnesota
Ronald Stein, JD, MSN, NP-C, AOCNP
Oncology Nurse Practitioner
Clinical Instructor of Medicine
Medical Oncology, USC Norris Cancer Center
USC Department of Medicine
Los Angeles, California
Seth Wander, MD, PhD
Assistant Professor of Medicine
Harvard Medical School
Attending Physician
Massachusetts General Hospital
Boston, Massachusetts
Meeting space has been assigned to provide a satellite symposium supported by AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Novartis, and Stemline Therapeutics Inc during the Oncology Nursing Society’s (ONS) 50th Annual Congress, April 9-13, 2025 in Denver, Colorado. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
Program Schedule — Mountain Time
5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 8:00 PM — Educational Meeting
Role of CDK4/6 Inhibitors for Localized Hormone Receptor (HR)-Positive Breast Cancer
Clinical factors that convey a high risk of disease recurrence in patients with HR-positive breast cancer; rationale for the addition of CDK4/6 inhibitors to standard adjuvant endocrine therapy for this population
Long-term findings with the addition of abemaciclib to adjuvant hormonal therapy for patients with HR-positive, HER2-negative breast cancer at high risk for recurrence
Published data with adjuvant ribociclib and endocrine therapy for patients with HR-positive, HER2-negative localized breast cancer and a high risk of recurrence
FDA-approved indications for adjuvant abemaciclib and ribociclib and identification of appropriate candidates for their use
CDK4/6 Inhibitors for HR-Positive Metastatic Breast Cancer (mBC)
Long-term follow-up data with abemaciclib, palbociclib and ribociclib for HR-positive mBC
Factors affecting the selection of a CDK4/6 inhibitor and an endocrine partner for premenopausal and postmenopausal patients
Role of CDK4/6 inhibitors in unique patient populations (eg, those with aggressive visceral disease, those with CNS metastases)
Tolerability and Other Practical Considerations with CDK4/6 Inhibitors
Spectrum and frequency of clinically relevant hematologic and nonhematologic toxicities, including cytopenias, gastrointestinal (GI) events, interstitial lung disease/pneumonitis and venous thromboembolic events, with CDK4/6 inhibitors
Optimal monitoring for and management of CDK4/6 inhibitor-associated toxicities
Comparative tolerability of CDK4/6 inhibitors in the adjuvant and metastatic settings; appropriate threshold for dose reduction/delay or treatment discontinuation in patients with breast cancer undergoing potentially curative therapy
Recommended duration of CDK4/6 inhibitor therapy in the adjuvant setting
Available PI3K Inhibitors for HR-Positive mBC
Prevalence and prognostic significance of PIK3CA mutations in HR-positive mBC; optimal timing and methodology for identification
Key findings with inavolisib in combination with palbociclib and fulvestrant as first-line therapy for patients with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative mBC
FDA approval of inavolisib with palbociclib and fulvestrant as up-front therapy for HR-positive, HER2-negative mBC with a PIK3CA mutation
Mechanistic similarities and differences between inavolisib and alpelisib; long-term data with alpelisib-based treatment for progressive HR-positive mBC with a PIK3CA mutation
Adverse Events (AEs) Associated with Available PI3K Inhibitors
Specificity of inavolisib and implications for its tolerability relative to alpelisib
Spectrum, frequency and severity of toxicities documented with inavolisib- and alpelisib-containing therapy
Appropriate strategies to monitor for, prevent and manage PI3K inhibitor-related toxicities
Clinical Utility of Capivasertib for HR-Positive mBC
Reported incidence of genomic alterations in the PTEN/PI3K/AKT pathway beyond PIK3CA mutations in HR-positive mBC
Biological rationale for inhibiting AKT in HR-positive mBC; mechanism of action of capivasertib
Key efficacy and safety data with capivasertib/fulvestrant for recurrent HR-positive, HER2-negative mBC
FDA approval of capivasertib for patients with PIK3CA/AKT1/PTEN alterations and current role among other evidence-based options
Side Effects and Other Practical Considerations with Capivasertib
Recommended monitoring and management strategies for diarrhea and other GI disorders in patients receiving capivasertib
Pathophysiology, spectrum and optimal treatment of cutaneous adverse reactions with capivasertib
Incidence of hyperglycemia with capivasertib; indications for blood glucose monitoring and role, if any, in patients with preexisting diabetes
Dose, schedule and recommended approach to dose reductions with capivasertib
Current and Future Role of Oral Selective Estrogen Receptor Degraders (SERDs) in HR-Positive mBC
Prevalence of ESR1 mutations in HR-positive mBC; optimal timing and approach to testing
Major findings with elacestrant for patients with pretreated HR-positive, HER2-negative mBC; outcomes in individuals with and without ESR1 mutations
Recently presented results with imlunestrant as monotherapy and combined with abemaciclib for patients with HR-positive, HER2-negative mBC pretreated with endocrine therapy
Emerging progression-free survival advantage documented with a switch from an aromatase inhibitor to camizestrant after detection of an emergent ESR1 mutation during first-line therapy for HR-positive, HER2-negative mBC
Current and future role of oral SERDs alone and in combination with other systemic therapies for HR-positive, HER2-negative mBC
Tolerability/Toxicity Profiles of Oral SERDs
Spectrum and incidence of common AEs observed with oral SERDs; comparative side-effect profiles of approved and investigational agents in this class
Pathophysiology of the hyperlipidemia observed with elacestrant; optimal monitoring of lipid profiles and other laboratory values in patients receiving oral SERDs
Recommended prophylaxis for and management of GI toxicities associated with elacestrant
Strategies to encourage adherence among patients with HR-positive, HER2-negative mBC receiving oral SERDs
Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.
Learning Objectives
Upon completion of this activity, participants should be able to
Consider available clinical trial findings with CDK4/6 inhibitors for localized hormone receptor (HR)-positive, HER2-negative breast cancer, and identify patients for whom adjuvant treatment with one of these agents may be appropriate.
Appraise published efficacy and safety data from randomized clinical trials evaluating CDK4/6 inhibitors for HR-positive metastatic breast cancer (mBC) in order to appropriately counsel patients regarding the optimal clinical use of these agents.
Review available research documenting the correlation between the presence of various biomarkers (eg, PIK3CA/AKT1/PTEN alterations, ESR1 mutations) and response to specific therapies in patients with HR-positive mBC.
Recall the frequency of phosphoinositide-3 kinase pathway mutations in patients with HR-positive mBC, and recognize the evidence-based approaches available to target these aberrations in individuals with PIK3CA-mutated disease.
Interrogate published Phase III research documenting the efficacy of AKT inhibitors for progressive HR-positive mBC to determine the current clinical applicability of this approach.
Understand the mechanism of action of, published and emerging research findings with and the current and future clinical role of oral selective estrogen receptor degraders for patients with HR-positive mBC harboring ESR1 mutations.
Discern the side effects and toxicities associated with available and investigational endocrine-based therapies for breast cancer, and identify strategies to manage and mitigate them.
Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
Credit Designation Statements
This educational activity for 2.0 contact hours is provided by Research To Practice.
This activity is awarded 2.0 ANCC pharmacotherapeutic contact hours.
Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2025/HRPositiveBreastCancer/ILNA
Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.
Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
Dr Borges — Advisory Committees: AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, Olema Oncology, Pfizer Inc, Seagen Inc; Consulting Agreements: Gilead Sciences Inc, Olema Oncology; Contracted Research: Agendia Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Gilead Sciences Inc, Olema Oncology, Pfizer Inc, Seagen Inc; Data and Safety Monitoring Boards/Committees: Pfizer Inc, Seagen Inc (HER2CLIMB-02 trial); Nonrelevant Financial Relationships: Pearl Scientific LLC.
Ms Carroll — Advisory Committees: AstraZeneca Pharmaceuticals LP, Lilly, Merck, Novartis; Nonrelevant Financial Relationships: Clinical Care Options, Horizon CME, MJH Life Sciences, OncLive, Scientific Global.
Mr Stein — Advisory Committees: Biotheranostics Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP.
Dr Wander — Advisory Committees: Biovica International AB, Genentech, a member of the Roche Group, Hologic Inc, Pfizer Inc, Puma Biotechnology Inc, Regor Therapeutics Group; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Foundation Medicine, Lilly, Novartis; Contracted Research: Genentech, a member of the Roche Group, Lilly, Nuvation Bio, Pfizer Inc, Regor Therapeutics Group, Sermonix Pharmaceuticals; Data and Safety Monitoring Boards/Committees: Regor Therapeutics Group; Speakers Bureaus: Guardant Health, Lilly; Nonrelevant Financial Relationships: 2nd.MD.
Additional faculty to be announced.
RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Novartis, and Stemline Therapeutics Inc.
Hyatt Regency Denver at Colorado Convention Center
650 15th Street
Denver, CO 80202
Hotel Phone: (303) 436-1234
Meeting Room
Capitol Ballroom (Fourth Floor)
The Hyatt Regency Denver at Colorado Convention Center is the headquarters hotel for the 2025 ONS Congress and is adjacent to the Colorado Convention Center.
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.
There is no registration fee for this event. For the in-person symposium in Denver, preregistration is required as seating is limited.
NOTICE: Registration for this event is independent of registration for the 2025 ONS Congress.
IN-PERSON Registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
